- Report
- February 2024
- 120 Pages
Asia Pacific
From €4749EUR$4,950USD£4,107GBP
- Report
- March 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- May 2024
- 194 Pages
Global
From €5229EUR$5,450USD£4,522GBP
- Report
- March 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- September 2020
- 175 Pages
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
- Report
- June 2020
- 111 Pages
Global
From €4558EUR$4,750USD£3,941GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,223GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,277GBP
- Report
- August 2022
- 120 Pages
Global
From €4318EUR$4,500USD£3,734GBP
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- May 2021
North America
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- May 2021
Asia Pacific
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- May 2021
Middle East, Africa
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
From €2015EUR$2,100USD£1,742GBP
€2878EUR$3,000USD£2,489GBP
- Report
- March 2021
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
- Report
- April 2023
- 140 Pages
Global
From €4270EUR$4,450USD£3,692GBP
- Report
- March 2020
- 49 Pages
Global
€1265EUR$1,318USD£1,094GBP
The Irritable Bowel Syndrome (IBS) market is a subset of the Gastroenterology market. IBS is a chronic disorder of the digestive system that affects the large intestine. Symptoms include abdominal pain, bloating, constipation, and diarrhea. Treatment options include dietary changes, medications, and lifestyle modifications.
The IBS market is expected to grow due to increasing prevalence of the disorder, rising awareness of IBS, and the availability of new treatments. Additionally, the increasing demand for better diagnosis and treatment of IBS is expected to drive the market.
Some companies in the IBS market include Allergan, AstraZeneca, GlaxoSmithKline, Ironwood Pharmaceuticals, Novartis, Pfizer, Salix Pharmaceuticals, Shire, Sucampo Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more